Each antibody for melanoma is available as a 2ml, 7ml, or 25ml ready-to-use antibody as well as in concentrated form.  Perhaps the most exciting antibody is our pan Melanoma which contains four different clones in order to make the cocktail more sensitive and also more valuable as a diagnostic tool for metastatic melanoma.

Product List:

Melanoma; Pan (Concentrate)
	Species: Mouse Clones: MART-1; Clone M2-7C10, MART-1; Clone M2-9E3, Tyrosinase; Clone T311, Melanoma: HMB45. Isotype: Mouse IgG1 Species Reactivity: Human. Positive Control: Human Melanoma Specificity: HMB45 has been shown to be a very specific marker for melanomas.
Melanoma; Pan (Ready-To-Use)
	Species: Mouse Clones: MART-1; Clone M2-7C10, MART-1; Clone M2-9E3, Tyrosinase; Clone T311, Melanoma: HMB45. Isotype: Mouse IgG1 Species Reactivity: Human. Positive Control: Human Melanoma Specificity: HMB45 has been shown to be a very specific marker for melanomas.
MART-1; Clones M2-7C10 & M2-9E3 (Ready-To-Use)
	Species: Mouse Clones: M2-7C10 & M2-9E3 Isotype: Mouse IgG2b, kappa Species Reactivity: Human. Positive Control: Human Melanoma. Specificity: MART-1 has been shown to be a very specific marker for melanomas.
MART-1; Clones M2-7C10 & M2-9E3 (Ready-To-Use)
	Species: Mouse Clones: M2-7C10 & M2-9E3 Isotype: Mouse IgG2b, kappa Species Reactivity: Human. Positive Control: Human Melanoma. Specificity: MART-1 has been shown to be a very specific marker for melanomas.
Tyrosinase; Clone T311 (Concentrate)
	Species: Mouse Clone: T311 Isotype: Mouse IgG1 Species Reactivity: Human. Positive Control: Human Melanoma Specificity: Tyrosinase has been shown to be a very specific marker for melanomas, not cross reacting with other tumors or normal tissues tested.
Tyrosinase; Clone T311 (Ready-To-Use)
	Species: Mouse Clone: T311 Isotype: Mouse IgG1 Species Reactivity: Human. Positive Control: Human Melanoma Specificity: Tyrosinase has been shown to be a very specific marker for melanomas. Cross reactivity with other tumors or normal tissues tested has not been reported.
MART-1; Clone M2-9E2 (Concentrate)
	Species: Mouse Clone: M2-9E2 Isotype: Mouse IgG2b, Kappa Species Reactivity: Human, Mouse, Rat. Positive Control: Metastatic melanoma in lymph nodes. Specificity: The clone M2-9E2 MART-1 antibody labels melanomas and other tumors showing melanocyte differentiation.
MART-1; Clone M2-9E2 (Ready-To-Use)
	Species: Mouse Clone: M2-9E2 Isotype: Mouse IgG2b, Kappa Species Reactivity: Human, Mouse, Rat. Positive Control: Metastatic melanoma in lymph nodes. Specificity: The clone M2-9E2 MART-1 antibody labels melanomas and other tumors showing melanocyte differentiation.
MART-1; Clone M2-7C10 (Concentrate)
	Species: Mouse Clone: M2-7C10 Isotype: Mouse IgG2b, Kappa Species Reactivity: Human. Clone M2-7C10 does not react with mouse or rat. Positive Control: Metastatic melanoma in lymph nodes. Specificity: The clone M2-7C10 MART-1 antibody labels melanomas and other tumors showing melanocyte differentiation.
MART-1; Clone M2-7C10 (Ready-To-Use)
	Species: Mouse Clone: M2-7C10 Isotype: Mouse IgG2b, Kappa Species Reactivity: Human. Clone M2-7C10 does not react with mouse or rat. Positive Control: Metastatic melanoma in lymph nodes. Specificity: The clone M2-7C10 MART-1 antibody labels melanomas and other tumors showing melanocyte differentiation.
S-100, Clone 4C4.9
	Species: Mouse Monoclonal Clone: 4C4.9 Isotype: IgG2a MW: 21-24 kD Species Reactivity: Human, Cow, Mouse Positive Control: Melanoma or Schwannoma. Specificity: Recognizes proteins of 21-24kDa, identified as the A and B subunits of S100 protein. S100 belongs to the family of calcium binding proteins such as calmodulin and troponin C. S100A is composed of an alpha and beta chain whereas S100B is composed of two beta chains. Antibody to S100 stains Schwannomas, ependymomas, astrogliomas, almost all benign and malignant melanomas and their metastases. S100 protein is also expressed in the antigen presenting cells such as the Langerhans cells in skin and interdigitating reticulum cells in the paracortex of lymph nodes. S100 protein is highly soluble and may be eluted from frozen tissue during staining.
Melanoma; Clone HMB45 (Concentrate)
	Species: Mouse Clone: HMB45 Isotype: Mouse IgG1/ Kappa Species Reactivity: Human Positive Control: Human Melanoma Specificity: HMB45 has been shown to be a very specific marker for melanomas.
Melanoma; Clone HMB45
	Species: Mouse Monoclonal Clone: HMB45 Isotype: IgG1 Species Reactivity: Human. Does not react with dog and rat. Positive Control: Melanoma Specificity: By immunohistochemistry, it specifically recognizes a protein in melanocytes and melanomas. Biochemical nature of its antigen is yet not fully characterized. This antibody reacts with junctional and blue nevus cells and variably with fetal and neonatal melanocytes. Intradermal nevi, normal adult melanocytes, and non-melanocytic cells are negative. It does not stain tumor cells of epithelial, lymphoid, glial, or mesenchymal origin.

Click here for Prices!

Redness, pain, and burns after unreasonably long exposure to solar radiation can be consigned to history when scientists recently discovered molecule in the composition of the skin, which is responsible for these reactions.
 
Blocking molecule TRPV4, which is abundant in the epidermis proven protects skin from harmful effects of the sun.

According to team leader Professor Wolfgang Liedtke, neurobiologist at the Medical University of North Carolina, their discovery enables the introduction of new products, which offer much greater protection for the skin.
 
Most skin burns were induced by ultraviolet radiation type B or UVB, which are useful in small amounts and facilitate the synthesis of 25-hydroxyvitamin D, as well as reducing the risk of many infectious diseases, because of the sterilizing effect.

However, too long exposure to UVB - over 30 minutes a day, cause DNA damage in skin cells, which dramatically increases the risk of developing skin cancer.
 
In the laboratory, scientists were able to completely block TRPV4 molecule in skin tissue through genetic engineering application. After irradiation normal and genetically modified skin with UVB rays with the same intensity and duration, the researchers reported excellent results: normal skin demonstrated redness, swelling and blisters normal for a typical sunburn while special skin devoid of TRPV4 was only slightly irritated.

Scientists already tested with great success and an ointment that is applied to the already burnt skin and removes the pain completely.
 
If their development be released will allow spend many more hours in the sun without leading to a risk of burns or skin cancer. Researchers note that the extended stay in the sun is beneficial not only for the synthesis of 25-hydroxyvitamin D, but also to lower the blood pressure and the risk of cardiovascular disease.

The ink used to make the tattoo may mask signs of melanoma.
 
29 year old German went through laser removal tattoo not after experts found the risk of melanoma.
 
Prior to completely eradicate tattoos chest and arms the young doctors can not be sure whether the condition is malignant because the ink changing skin pigmentation and prevents to make relevant research.

The removal of any of the pictures it took seven years for a total of 43 sessions with a laser.
 
By biopsy clean tattoos skin specialists establish superficial malignant melanoma, the most common form of melanoma.

Superficial spreading melanoma affects the top layer of skin. 50% of cases from the existing mole. When the body is depicted with tattoos, however, this makes it difficult to see the change in color of the skin around the mole, an indication of the risk of cancer, experts explain.

The authors reported the case in JAMA Dermatology 2013, reported 16 more cases of melanoma patients with tattoos where the laser removal has led to a delay in diagnosis and death.
 
Experts note that the ink used to make the tattoo covers indicators for melanoma, but there is no evidence that it is the cause of this cancer.

Most adults have between 10 and 40 moles on their bodies, and the distinction between innocent dark speck of a cancer is not easy.
 
Dr. Mary Lupo, consultant dermatologist from New Orleans advises the skin of the whole body can be accessed once a month and it's not alone. This could help a close, preferably once and later as instructed to do consult a dermatologist, who can focus on certain features of the skin individually.

On moles should be monitored for some strictly defined factors: color, position, size and integrity.

If there is something offensive about unemployment of a mole on her should be given special attention. Pinkish spot from which or about which there is a scaly skin, not available sunburn and is usually located on the face, hands or shoulders is often the first suspect - actinic keratosis. They quickly pass. In over 20% of cases, however, these "precancerous" formations lead to squamous cell carcinoma. Patients and even dermatologists might confuse these signs of eczema, but it does not go alone with such speed.

Speck that looks fresh pink and shiny, located on the head, neck or ears can be basal cell carcinoma. This most common type of skin cancer rarely metastasizes, but its formation are especially dangerous. Statistically, if it is an ear or lip lies strongly increased risk of spread to the lymph nodes and from there - to the lungs.

Reddish, scaly and slightly elevated above the rest leather stain hiding potential of squamous cell carcinoma. You may have lesions - small wounds that have a high potential for metastasis and often can be fatal.
 
Spots that are asymmetric with uneven shapes and colors, irrespective of where the body, most often a sign of melanoma - the most fatal form of skin cancer. Its formations are usually close to the size of an eraser on a pencil. Their color can be overflowing or heterogeneous and include: dark blue or dark red, deep brown and

The most deadly form of skin cancer - melanoma, has its unique signature of chemicals found scientists from Monell Chemical Senses Center and the University of Pennsylvania in Philadelphia. The survey can help opening new, non-invasive method for the diagnosis of melanoma at an early stage. The discovery was published in the special report in the journal Journal of Chromatography B.

Melanoma is the most aggressive and dangerous type of skin cancer. It is characterized by rapid growth and early spread to other parts of the body.
Melanoma is a typical black because melamine synthesized by the cells. However, there are colorless (leuco-melanoma), in the course of their malignant tumor cell degeneration have lost the ability to synthesize a pigment. These melanomas usually more malignant than black.

The relationship between the melanoma cells is very weak. They are easily removed from the tumor and were brought through the blood or lymph. Therefore melanoma metastasizes very early and abundantly throughout the body - regional lymph nodes, internal organs, muscles, bones, brain, and if the patient has other cancers - even in them. Likewise, melanoma cells are generally well-differentiated, which makes them less sensitive to chemotherapy and radiation therapy, and reduces the immune response against them, and this contributes to the rapid growth of the tumor.

For his research team scientists from University of Pennsylvania used the samples grown in the laboratory melanomas in three stages of development, and healthy cells. Once individual samples proved that there are significant differences in the concentration of certain chemicals that produce odors between normal cells and those infected with melanomas.

Researchers are even able to "see" the differences between different types of melanoma cells from detaching from their chemical signatures.

FDA has approved two drugs to GlaxoSmithKline for the treatment of advanced melanoma - the most aggressive skin cancer patients with specific genetic mutations. Regulatory approvals, and diagnostic test for demonstrating these mutations.
 
The drugs are approved for administration separately, once in two separate clinical trials, they showed delayed tumor growth.

After decades of virtually no progress in the fight against advanced melanoma, two new drugs celebrated turn in favor of medicine. Over the past two years, FDA has approved a total of 4 new drugs this indication.
 
Each year in the U.S. from melanoma ill about 75 000 people. The mortality rate is around 9,000 to 10,000 per year.
 
Forecast sales for each of the two new drugs are about 350 million dollars a year.

Medicine for the treatment of cancer based on a virus destroying tumor cells for the first time successfully passed clinical trials in advanced stage, said U.S. pharmaceutical manufacturer Amgen.

A statement from the company product has achieved the main objective of the Phase III clinical trial in patients with advanced melanoma - the most aggressive type of skin cancer. The results showed that 16% of patients who received treatment had a significant tumor poured lasting six months or more, compared with only 2% of the control group.

A spokesman for the company declined to say whether the company will apply for registration to the FDA on the basis of this study.

It contains the virus Talimogene laherparepvec, genetically modified in a way that causes him to multiply only in rapidly growing cells. The product is injected directly into the tumor, after which the virus enters the cancer cells and causes them to synthesize large amounts of granulocyte-monocyte colony stimulating factor - the hormone that stimulates the maturation of immune cells. When cancerous cells die, they release new amounts of virus and acquired therein colony stimulating factor, which boost the immune system.

The study was conducted in 400 patients, two thirds of whom received injections every two weeks. The rest of the participants received injections only granulocyte-monocyte colony stimulating factor. According to Dr. Anthony Ribas, melanoma specialist at the University of Los Angeles, the study results are positive, but it is uncertain whether sufficient authorization for use.